[Prophylactic use of @entity3397 and XXXX in @entity64 . I. Clinical observations].

@entity1 @entity64 @entity55 @entity114 @entity3397 @entity869 @entity166 @entity293
In 103 @entity1 with @entity64 without associated infections the prophylactic usefulness of antibiotics was assessed clinically. In 30 @entity1 (group I) and 27 @entity1 (group II) @entity869 was used in daily doses of 2-4 g or @entity114 (Polfa) was given 2.4-4.8 million i.u. during 10 days. In the remaining 46 cases (group III) no antibiotics were given and these @entity1 served as controls. During the first 10 days after @entity64 onset @entity166 complications developed significantly less frequently in controls (in 15 cases, i.e. 33%) than in those receiving antibiotic phophylaxis (40 cases i.e. 70%). The difference between the groups was statistically significant (p less than 0.001). In the second ten-day period no clinical evidence of new infection was observed in any group. It may be supposed in the light of these diseases that administration of @entity3397 or @entity869 to @entity1 with @entity64 without carrying out antibiotic sensitivity tests is unnecessary. Nearly exclusively @entity55 and @entity293 appear in the first ten days after @entity64 onset which may suggest acute and gradually levelling-off of the neuroregulation of immunological defense mechanisms.
